Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.75 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.75 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminoglutethimide SCHEMBL4306 | 0.86 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL116988 | 0.86 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL1230613 | 0.86 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL7728932 | 0.86 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Glutethimide SCHEMBL113709 | 0.85 | CYP19A1 (0.72) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Glutethimide SCHEMBL113708 | 0.85 | CYP19A1 (0.72) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Glutethimide SCHEMBL21119240 | 0.85 | CYP19A1 (0.72) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL28457203 | 0.84 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL20135217 | 0.83 | CYP19A1 (0.73) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL16887943 | 0.83 | CYP19A1 (0.69) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306671-A1 | AMIDE DERIVATIVES OF ETHACRYNIC ACID | The Regents of the The University of California (US) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306671-A1 | AMIDE DERIVATIVES OF ETHACRYNIC ACID | EPX, TNF, NFKBIA | CYP19A1 1070/4885CYP3A4 3504/4885CYP17A1 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.